Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT04176198
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- NCT04176198 ↗
- Recruiting
- Sumitomo Pharma America, Inc.
- Focused
We haven't built an HCP commentary report on NCT04176198 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04176198 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Myelofibrosis
- Interventions
- Nusivertib; Ruxolitinib; Momelotinib
- Arms
- Arm 1: nuvisertib (TP-3654) · Experimental
- Arm 2: nuvisertib (TP-3654) added on to ruxolitinib · Experimental
- Arm 3: nuvisertib (TP-3654) in combination with momelotinib · Experimental
- Enrollment
- 240 (estimated)
- Primary outcomes
- Determine the incidence of dose-limiting toxicities (DLTs)
- Determine the incidence of treatment emergent adverse events
- Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)
- Sponsor
- Sumitomo Pharma America, Inc.
- Start
- Dec 16, 2019
- Primary completion
- Apr 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04176198 · updated Oct 2, 2026